CANCER, GENOMICS AND CONSULTING LTD

Executive Summary

Cancer, Genomics and Consulting Ltd is a promising micro-sized enterprise leveraging a unique combination of medical, biotechnological, and IT consulting expertise to address emerging needs in precision oncology. Its strong financial footing and strategic location underpin growth potential through service expansion and partnerships, though scaling operational capacity and managing regulatory complexities remain critical challenges to ensure sustainable competitive advantage.

CANCER, GENOMICS AND CONSULTING LTD - Analysis Report

Company Number: 13515820

Analysis Date: 2025-07-20 18:06 UTC

1. Executive Summary
   Cancer, Genomics and Consulting Ltd is a micro-sized private limited company operating within a highly specialized niche intersecting medical practice, biotechnology R&D, scientific consulting, and IT consultancy. Founded in 2021 and led by a single director with significant domain expertise, the company has demonstrated solid asset growth and equity build-up, positioning itself as an emerging player in precision oncology and genomics consulting services.

2. Strategic Assets

• Specialized Expertise: The company’s SIC codes indicate a unique blend of medical practice (86220), biotechnology research (72110), and scientific/IT consulting (71122, 62020). This multidisciplinary approach creates a competitive moat through integrated service offerings that few competitors can match.
• Founder-Led Focus: Dr. Alexander Aresh Azizi holds full ownership and control, providing agile decision-making and a clear strategic vision aligned with cutting-edge scientific advancements.
• Strong Financial Foundation: The company has expanded net assets from £1 in 2021 to nearly £54k in 2024, reflecting prudent financial management and positive working capital (£64k current assets vs. £9k current liabilities). This financial stability supports continued investment in R&D and service development.
• Location Advantage: Based in Babraham, Cambridge, a renowned biotech cluster, the company benefits from proximity to leading research institutions and potential collaboration partners, enhancing innovation capacity and market credibility.

3. Growth Opportunities

• Expansion of Service Portfolio: Leveraging its biotechnology and IT consulting capabilities, the company can develop proprietary genomics analytics tools or platforms tailored for cancer diagnostics, tapping into the growing precision medicine market.
• Strategic Partnerships and Collaborations: Forming alliances with academic institutions, pharmaceutical companies, and healthcare providers can accelerate R&D efforts, broaden client base, and open revenue streams through collaborative projects.
• Market Penetration in Clinical and Research Segments: Targeting specialized oncology clinics and research organizations that require genomics-driven insights offers scalable consulting engagements and potential retainer contracts.
• Digital Transformation and Data Services: Enhancing IT consultancy with advanced bioinformatics and AI-driven data analytics solutions will differentiate offerings and meet increasing demand for data-centric cancer research support.

4. Strategic Risks

• Scale and Resource Constraints: With only one employee (the director), operational scalability and capacity to deliver multiple or large-scale projects simultaneously are limited, potentially restricting growth velocity.
• Market Education and Adoption Barriers: The niche nature of genomics consulting requires ongoing market education, and adoption may be impeded by entrenched practices or budget constraints within target clients.
• Regulatory and Compliance Exposure: Operating in healthcare and biotech sectors involves navigating complex regulatory frameworks, which may impose compliance costs and operational risks if not proactively managed.
• Dependence on Key Individual: Heavy reliance on the director’s expertise and leadership poses succession and continuity risks. Any disruption could impact client relationships and strategic momentum.